Click here to close now.




















Welcome!

News Feed Item

Treatment Algorithms: Postherpetic Neuralgia - Lyrica forms the cornerstone of treatment for postherpetic neuralgia

NEW YORK, Dec. 17, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Treatment Algorithms: Postherpetic Neuralgia – Lyrica forms the cornerstone of treatment for postherpetic neuralgia

http://www.reportlinker.com/p01055536/Treatment-Algorithms-Postherpetic-Neuralgia-–-Lyrica-forms-the-cornerstone-of-treatment-for-postherpetic-neuralgia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Prescribing trends reveal that patients with PHN are typically initiated on monotherapy. Since no single therapy provides sufficient efficacy, physicians increasingly turn to combination therapy at later lines of treatment to optimize patient outcomes. Lyrica (pregabalin; Pfizer) leads the market, with the recent market entrant Gralise (extended-release gabapentin) struggling to make an impact.Gain insight into patient presentation, diagnosis, and treatment rates and understand which physician types are responsible for management of PHN.Quantify the PHN population across the seven major markets by pain severity (mild, moderate, and severe).Understand which drug treatments are the most commonly prescribed and how this differs across line of therapy and geographic region.Analyze the class, formulation, and brand prescribing trends in the seven major markets.Understand the response rate of patients across three lines of therapy and rates of progression from first to second and third lines of therapy.Following first-line therapy, combination therapies become the mainstay of treatment regimens for the management of PHN, as physicians attempt to optimize therapeutic outcomes. Therefore positioning treatments as adjuvant therapy represents a key opportunity for drug developers.With the vast majority of patients prescribed anticonvulsants as first-line therapy, this treatment class represents the key competition to prospective market entrants. Widespread, off-label prescribing of antidepressants also represents a significant competitive barrier within the PHN market.Lyrica (pregabalin; Pfizer) is the leading brand in the PHN market. Generally, branded products are well received in the market, accounting for the majority of treatments prescribed at first-line therapy.What drugs are the most commonly prescribed for the management of PHN in each of the seven major markets?What are the current PHN market dynamics and the competitive landscape in terms of patient numbers?How can drug developers optimize patient share and position new products appropriately within the PHN market?Which physician types are primarily responsible for PHN prescribing decisions and are therefore key targets for marketing efforts for PHN treatments?What proportion of patients responds to first-line therapy and what proportion progress to second and third lines of therapy?

OVERVIEW

Summary

EXECUTIVE SUMMARY

Datamonitor key findings

COUNTRY TREATMENT TREES

Introduction to treatment trees

Seven major markets

US

Japan

France

Germany

Italy

Spain

UK

DISEASE DEFINITION AND DIAGNOSIS

Disease definition

Etiology

Postherpetic neuralgia results from nerve damage caused by the herpes zoster virus

There are three key points of influence in the prevention of postherpetic neuralgia

Symptoms

Presentation and diagnosis

Less than two thirds of individuals with symptoms of postherpetic neuralgia present to a physician

Of individuals presenting to physicians with symptoms of PHN, 58% receive a diagnosis of PHN

Treatment rates

Across the seven major markets, 37% of diagnosed PHN patients do not receive pharmacological treatment

Influences on diagnosis and treatment rates

Identification of patients at risk of developing PHN is key to capturing the potential treatment market

Referral patterns

Patients with PHN are predominantly managed by primary care physicians/general practitioners

PATIENT SEGMENTATION

Severity of postherpetic neuralgia

The majority of patients with postherpetic neuralgia suffer from moderate to severe pain

Symptoms associated with pain in PHN

Burning sensation, shooting pain, and interrupted sleep are the key pain-associated symptoms in PHN

CURRENT TREATMENT OPTIONS

Overview of drug classes

Only five patented products are indicated for the treatment of postherpetic neuralgia

Anticonvulsants

Antidepressants

Opioids

Topical treatments

PRESCRIBING TRENDS

Class trends

Anticonvulsants are the most commonly prescribed drug class for PHN across all lines of therapy

Across the seven major markets antidepressants are frequently prescribed off-label for PHN

The US has the highest level of opioid prescribing for postherpetic neuralgia

Poor perception of efficacy leaves local anesthetics as the fourth most frequently prescribed drug class

Anxiolytic and antiarrhythmic treatments are not widely prescribed for the management of PHN

Formulation trends

Oral treatments dominate the treatment of postherpetic neuralgia at all lines of therapy

Combination therapy trends

Combination therapy is the mainstay at second and third-line therapy in order to optimize patient outcomes

Prescribing of brands versus generics

Branded products are favored for the first-line management of PHN

Changes in therapy

Lyrica monotherapy dominates the market as the top therapeutic option across all lines of therapy

Lyrica continues to dominate at second-line therapy

Treatments struggle to dominate later lines of therapy amid a vast range of different therapeutic options

Lidoderm and Lyrica provide models of successful PHN treatments in the US market

Patients with PHN increasingly spend longer on second and third-line therapy

Treatment outcomes

Response to therapy

Progression through lines of therapy

Compliance to therapy

BIBLIOGRAPHY

Journal papers

Websites

APPENDIX A

Physician research methodology

Physician sample breakdown

The survey questionnaire

Screener

APPENDIX B

Contributing experts

Conferences attended

TABLES

Table: Summary of drug classes and molecules used for the treatment of postherpetic neuralgia, 2012

Table: The proportion of patients across the seven major markets receiving monotherapy or combination therapy, across different lines of therapy, in the seven major markets, 2012

Table: The top 20 first-line treatments for postherpetic neuralgia across the seven major markets and the proportion of patients receiving these therapies in the individual markets, 2012

Table: The top 20 second-line treatments for postherpetic neuralgia across the seven major markets and the proportion of patients receiving these therapies in the individual markets, 2012

Table: The top 20 third-line treatments for postherpetic neuralgia across the seven major markets and the proportion of patients receiving these therapies in the individual markets, 2012

Table: Treatment response among patients with postherpetic neuralgia across the seven major markets, 2012

Table: Physicians surveyed regarding neuropathic pain across the seven major markets, 2012

FIGURES

Figure: Postherpetic neuropathic pain treatment algorithm in the US, 2012

Figure: Postherpetic neuropathic pain treatment algorithm in Japan, 2012

Figure: Postherpetic neuropathic pain treatment algorithm in France, 2012

Figure: Postherpetic neuropathic pain treatment algorithm in Germany, 2012

Figure: Postherpetic neuropathic pain treatment algorithm in Italy, 2012

Figure: Postherpetic neuropathic pain treatment algorithm in Spain, 2012

Figure: Postherpetic neuropathic pain treatment algorithm in the UK, 2012

Figure: Etiology of postherpetic neuralgia

Figure: Common sites for shingles and subsequent postherpetic neuralgia

Figure: Percentage of individuals with the symptoms of postherpetic neuralgia presenting to physicians, 2012

Figure: The diagnosis rate of individuals presenting to physicians with the symptoms of postherpetic neuralgia, 2012

Figure: The percentage of patients diagnosed with postherpetic neuralgia receiving pharmacological treatment, 2012

Figure: A screenshot of patient-centric educational material regarding postherpetic neuralgia, produced by Depomed, 2011

Figure: Percentage of postherpetic neuralgia patients across the seven major markets who are managed by different healthcare professionals during patient presentation, diagnosis, treatment, and management, 2012

Figure: Patient segmentation by severity of postherpetic neuralgia pain, across the seven major markets, 2012

Figure: Percentage of patients experiencing pain associated with the symptoms of postherpetic neuralgia, 2012

Figure: The impact of postherpetic neuralgia symptoms on patients, as rated by surveyed physicians, 2012

Figure: Proportion of patients with postherpetic neuralgia receiving different classes of therapy at three lines of therapy, across the seven major markets, 2012

Figure: The percentage of patients receiving each drug class as first-line therapy across the seven major markets, 2012

Figure: The relative proportion of therapies, by formulation, that patients are prescribed for the management of postherpetic neuralgia, 2012

Figure: The percentage of patients with postherpetic neuralgia receiving combination or monotherapy across different lines of therapy, in the seven major markets, 2012

Figure: The relative proportion of branded versus generic products prescribed for the first-line management of postherpetic neuralgia across the seven major markets, 2012

Figure: The relative percentage of branded or generic drug therapies prescribed to patients in the seven major markets, Spain, and the UK, 2012

Figure: The percentage of patients receiving branded products as first-line therapy, by drug class, across the seven major markets, 2012

Figure: The top 10 first-line treatments for postherpetic neuralgia across the seven major markets and the proportion of patients receiving these therapies in the individual markets, 2012

Figure: The top 10 second-line treatments for postherpetic neuralgia across the seven major markets and the proportion of patients receiving these therapies in the individual markets, 2012

Figure: The top 10 third-line treatments for postherpetic neuralgia across the seven major markets and the proportion of patients receiving these therapies in the individual markets, 2012

Figure: The proportion of patients receiving key FDA-approved therapies, either as monotherapy or combination therapy, for the management of postherpetic neuralgia, across all lines of therapy in the US, 2012

Figure: The mean number of weeks patients with postherpetic neuralgia spend on first, second, and third-line therapy, across the seven major markets, 2012

Figure: Percentage of postherpetic neuralgia patients responding to first-line therapy across the seven major markets, 2012

Figure: The percentage of patients who progress through three lines of pharmacotherapy across the seven major markets, 2012

Figure: Mean compliance rate across the seven major markets, by type of therapeutic regimen, 2012

Figure: Reasons for patients' non-compliance to therapy in neuropathic pain, 2012

Figure: First-line treatment of postherpetic neuralgia

Figure: Second-line treatment of postherpetic neuralgia

Figure: Third-line treatment of postherpetic neuralgia

Companies Mentioned

Choices, Devoteam SA, GlaxoSmithKline Plc, Hutchison 3G UK Limited, Schindler Holding Ltd.

To order this report:Therapy Industry: Treatment Algorithms: Postherpetic Neuralgia – Lyrica forms the cornerstone of treatment for postherpetic neuralgia

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Amazon and Google have built software-defined data centers (SDDCs) that deliver massively scalable services with great efficiency. Yet, building SDDCs has proven to be a near impossibility for ‘normal’ companies without hyper-scale resources. In his session at 17th Cloud Expo, David Cauthron, founder and chief executive officer of Nimboxx, will discuss the evolution of virtualization (hardware, application, memory, storage) and how commodity / open source hyper converged infrastructure (HCI) so...
In their Live Hack” presentation at 17th Cloud Expo, Stephen Coty and Paul Fletcher, Chief Security Evangelists at Alert Logic, will provide the audience with a chance to see a live demonstration of the common tools cyber attackers use to attack cloud and traditional IT systems. This “Live Hack” uses open source attack tools that are free and available for download by anybody. Attendees will learn where to find and how to operate these tools for the purpose of testing their own IT infrastructu...
The web app is agile. The REST API is agile. The testing and planning are agile. But alas, data infrastructures certainly are not. Once an application matures, changing the shape or indexing scheme of data often forces at best a top down planning exercise and at worst includes schema changes that force downtime. The time has come for a new approach that fundamentally advances the agility of distributed data infrastructures. Come learn about a new solution to the problems faced by software organ...
With the Apple Watch making its way onto wrists all over the world, it’s only a matter of time before it becomes a staple in the workplace. In fact, Forrester reported that 68 percent of technology and business decision-makers characterize wearables as a top priority for 2015. Recognizing their business value early on, FinancialForce.com was the first to bring ERP to wearables, helping streamline communication across front and back office functions. In his session at @ThingsExpo, Kevin Roberts...
IBM’s Blue Box Cloud, powered by OpenStack, is now available in any of IBM’s globally integrated cloud data centers running SoftLayer infrastructure. Less than 90 days after its acquisition of Blue Box, IBM has integrated its Blue Box Cloud Dedicated private-cloud-as-a-service into its broader portfolio of OpenStack® based solutions. The announcement, made today at the OpenStack Silicon Valley event, further highlights IBM’s continued support to deliver OpenStack solutions across all cloud depl...
Red Hat is investing in Tesora, the number one contributor to OpenStack Trove Database as a Service (DBaaS) also ranked among the top 20 companies contributing to OpenStack overall. Tesora, the company bringing OpenStack Trove Database as a Service (DBaaS) to the enterprise, has announced that Red Hat and others have invested in the company as a part of Tesora's latest funding round. The funding agreement expands on the ongoing collaboration between Tesora and Red Hat, which dates back to Febr...
With the proliferation of connected devices underpinning new Internet of Things systems, Brandon Schulz, Director of Luxoft IoT – Retail, will be looking at the transformation of the retail customer experience in brick and mortar stores in his session at @ThingsExpo. Questions he will address include: Will beacons drop to the wayside like QR codes, or be a proximity-based profit driver? How will the customer experience change in stores of all types when everything can be instrumented and a...
The Internet of Things (IoT) is about the digitization of physical assets including sensors, devices, machines, gateways, and the network. It creates possibilities for significant value creation and new revenue generating business models via data democratization and ubiquitous analytics across IoT networks. The explosion of data in all forms in IoT requires a more robust and broader lens in order to enable smarter timely actions and better outcomes. Business operations become the key driver of I...
While many app developers are comfortable building apps for the smartphone, there is a whole new world out there. In his session at @ThingsExpo, Narayan Sainaney, Co-founder and CTO of Mojio, will discuss how the business case for connected car apps is growing and, with open platform companies having already done the heavy lifting, there really is no barrier to entry.
WSM International, the pioneer and leader in server migration services, has announced an agreement with WHOA.com, a leader in providing secure public, private and hybrid cloud computing services. Under terms of the agreement, WSM will provide migration services to WHOA.com customers to relocate some or all of their applications, digital assets, and other computing workloads to WHOA.com enterprise-class, secure cloud infrastructure. The migration services include detailed evaluation and planning...
SYS-CON Events announced today that DataClear Inc. will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. The DataClear ‘BlackBox’ is the only solution that moves your PC, browsing and data out of the United States and away from prying (and spying) eyes. Its solution automatically builds you a clean, on-demand, virus free, new virtual cloud based PC outside of the United States, and wipes it clean...
Culture is the most important ingredient of DevOps. The challenge for most organizations is defining and communicating a vision of beneficial DevOps culture for their organizations, and then facilitating the changes needed to achieve that. Often this comes down to an ability to provide true leadership. As a CIO, are your direct reports IT managers or are they IT leaders? The hard truth is that many IT managers have risen through the ranks based on their technical skills, not their leadership ab...
eCube Systems has released NXTmonitor, a full featured application orchestration solution. NXTmonitor, which inherited the code base of NXTminder, has been extended to support multi-discipline processes and will act as a DevOps utility in a heterogeneous enterprise environment. Previously, NXTminder was packaged with NXTera middleware to configure and manage Entera and NXTera RPC servers. “Since we are widening the focus of this solution to DevOps, we felt the need to change the name to NXTmon...
Contrary to mainstream media attention, the multiple possibilities of how consumer IoT will transform our everyday lives aren’t the only angle of this headline-gaining trend. There’s a huge opportunity for “industrial IoT” and “Smart Cities” to impact the world in the same capacity – especially during critical situations. For example, a community water dam that needs to release water can leverage embedded critical communications logic to alert the appropriate individuals, on the right device, as...
Everyone talks about continuous integration and continuous delivery but those are just two ends of the pipeline. In the middle of DevOps is continuous testing (CT), and many organizations are struggling to implement continuous testing effectively. After all, without continuous testing there is no delivery. And Lab-As-A-Service (LaaS) enhances the CT with dynamic on-demand self-serve test topologies. CT together with LAAS make a powerful combination that perfectly serves complex software developm...